Testing of VISTA as a target in MM would address a high clinical need as IMiDs, monoclonal antibodies, and more recently, the use anti-BCMA CAR T-cell therapy, still go hand-in-hand with a high relapse rate. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.